23.2 C
Rome
24.5 C
New York
20 C
London
Tuesday, July 27, 2021

The Weekly Update

Biogen defending Aduhelm; Roche talking with FDA for Alzheimer’s drug

Another week has passed, and the focus is still on Alzheimer. Biogen defending Aduhelm In the weekly update "The Run for Alzheimer", I've talked about the approval of Aduhelm, the controversial Alzheimer's drug approved by FDA earlier this June. The approval is moving many opinions in...

Moderna joined the S&P 500; Eli Lilly acquisition of Promoter Technologies

Moderna joined the S&P 500 Alexion Pharmaceutical (acquired by AstraZeneca last year*) is leaving the S&P 500 and Moderna is taking its place. If you are not familiar with the S&P indices, this description (From S&P Dow Jones Indices Linkedin page) could help you: S&P Dow Jones...

Philip Morris acquisition of Vectura; Pfizer booster shot

Euro 2020. Italy is the European Champion 🇮🇹.On Sunday the Italian team won against England. Philip Morris acquisition of Vectura The 9th of July, Philip Morris International (NYSE: PM) announced the offer to acquire Vectura Group (LON: VEC). Vectura is a British company that provides innovative inhaled...

The future of GSK

Big moves on GSK last days. If you didn’t follow the whole story, here there is a quick recap: On April 15, the Financial Times reported that the Hedge fund Elliott has built multibillion-pound stake in GlaxoSmithKline (NYSE: GSK).Elliott (Elliott Management Corporation) is an American investment...

The run for Alzheimer

From the Financial Times (June 7, 2021) US regulators have approved the first new treatment for Alzheimer’s disease in almost two decades, giving a green light to a drug developed by Biogen despite a rancorous scientific debate over whether the medicine works. If you have/had Biogen (NASDAQ: BIIB) shares...

Covid-19 vaccine update (AstraZeneca and the EU); Did Theranos teach us a lesson? (The case of Athira Pharma)

Last Friday, the EU has “lost” a legal bid to force AstraZeneca (interim decision) to speed up the delivery of 120 million vaccine doses cumulatively by the end of June 2021, and a total of 300 million doses by the end of September 2021. Instead of delivering...

The G7 Summit on pledging Covid-19 vaccines; Novavax vaccine candidate efficacy; CureVac Covid-19 Vaccine Update

The G7 on pledging vaccines The G7 hosted in Cornwall ended last Sunday. The leaders of the Group of Seven agreed on a shared agenda for Global Action to Build Back Better (after the Covid-19 Pandemic) mostly focused on end the pandemic, reinvigorate the seven economies and...

Read More

The Shorts

Biogen-Aduhelm FDA Approval update

The Food and Drug Administration (FDA) has changed the prescribing label for Biogen Alzheimer’s drug Aduhelm. Now, the use is recommended only to patients...

Covid-19 vaccine tracker and landscape

In this thread, I want to suggest a database that can help you to better track Covid-19 vaccine candidates, and that can be used...

Archives